Loading stock…

Haisco Pharmaceutical Group Co., Ltd. (002653) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated today

Haisco Pharmaceutical Group Co., Ltd.

002653Market cap $10BPrice $8.8

Country🇨🇳China

SectorHealthcare

IndustryPharmaceuticals

Develops and manufactures generic and specialty drugs across anesthesia, oncology, and infection treatment. One of China's largest anesthetic drugmakers, controlling a big enough share of the market that hospital surgeries nationwide often rely on its products.

In Bastion Portfolios?

52W Return+20%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+13%8

Revenue Forecast

Rev CAGR (1y)+67%10

Rev CAGR (3y)+20%9

Rev CAGR (5y)+14%8

Earnings Forecast

EPS Growth Y+1+196%10

EPS Growth Y+2+48%9

EPS Growth Y+3+23%8

Quality

Margins

EBIT Margin15%6

Net Income Margin17%7

Free Cash Flow Margin17%7

Debt

Net Debt/EBITDA0.27

Efficiency

ROE21%8

ROA13%9

Earnings Stability44

GEAR+STRONG85

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)801

P/E Ratio (Forward 3y)501

P/BV13.71

EV Multiples

EV/EBITDA Fwd341

EV/EBIT Fwd401

Yield

Free Cash Flow Yield1.4%3

Dividend Yield0.4%2

Momentum

Short term

1 month return-4%5

3 month return-5%5

YTD return+23%8

Mid term

Price vs 52wHigh74%4

1 year return+18%7

Long term

3 year return+176%9

5 year return+255%9

Risk Shield

Price Risk

Beta-0.310

Volatility52%3

Free Cash Flow

Free Cash Flow Margin17%7

Free Cash Flow Yield1.4%3

Quality

ROCE15%8

Earnings Stability44

Net Debt/EBITDA0.27

02Growth

Is it actually growing, and how fast?

002653Haisco Pharmaceutical Group Co.

Revenue FY25$627M

GROWTH RATING↗

VERY STRONG91 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+13%8

Revenue, next 1Y+67%10

Revenue, next 3Y, CAGR+20%9

Revenue, next 5Y, CAGR+14%8

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+196%10

EPS growth, FY27E+48%9

EPS growth, FY28E+23%8

GROWTH ASSESSMENT

STRENGTHS

It out-grows 91% of companies worldwide.

Revenue grew 13%/yr over the last 3 years, ahead of 70% of companies worldwide.8/10

Revenue is set to grow 20%/yr over the next 3 years, ahead of most of the market.9/10

Revenue grew 13%/yr over the last 3 years and is set to grow 20%/yr from here.

The runway holds up: revenue is set to grow 14%/yr over five years.8/10

Earnings are set to grow faster than sales (EPS about 48%/yr vs revenue 20%/yr), so margins should widen.

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Hyper Compounder

A top-tier grower that's speeding up.

03Price Momentum

Is the market behind it right now?

002653Haisco Pharmaceutical Group Co.

Total return Current343%

Price return Current292%

MOMENTUM RATING↗

AVERAGE62 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-4%5

3-month return-5%5

YTD return+23%8

MID & LONG-TERM▾SCORE

% of 52-week high74%4

1-year return+18%7

3-year return+176%9

5-year return+255%9

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +176% over three years and +255% over five, ahead of 80% of the market.

Strong recent results. The stock is outperforming so far this year (+23%).

WATCH

It's up 18% over the past year, but 26% below its 52-week high. That is a touch ahead of the market.

Returns sit at the market level over the past month (-4%) and over three months (-5%).

WEAKNESSES

None flagged.

BOTTOM LINE

Steady Compounder

Dependable multi-year returns with a calmer near-term tape. A reliable long-term trend rather than a short-term breakout.

04Value

Are you paying a fair price for it?

Stop guessing on Haisco Pharmaceutical Group Co., Ltd.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

002653Haisco Pharmaceutical Group Co.

Revenue FY25$627M

GROWTH RATING↗

VERY STRONG91 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+13%8

Revenue, next 1Y+67%10

Revenue, next 3Y, CAGR+20%9

Revenue, next 5Y, CAGR+14%8

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+196%10

EPS growth, FY27E+48%9

EPS growth, FY28E+23%8

GROWTH ASSESSMENT

STRENGTHS

It out-grows 91% of companies worldwide.

Revenue grew 13%/yr over the last 3 years, ahead of 70% of companies worldwide.8/10

Revenue is set to grow 20%/yr over the next 3 years, ahead of most of the market.9/10

Revenue grew 13%/yr over the last 3 years and is set to grow 20%/yr from here.

The runway holds up: revenue is set to grow 14%/yr over five years.8/10

Earnings are set to grow faster than sales (EPS about 48%/yr vs revenue 20%/yr), so margins should widen.

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Hyper Compounder

A top-tier grower that's speeding up.

03Price Momentum

Is the market behind it right now?

002653Haisco Pharmaceutical Group Co.

Total return Current343%

Price return Current292%

MOMENTUM RATING↗

AVERAGE62 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-4%5

3-month return-5%5

YTD return+23%8

MID & LONG-TERM▾SCORE

% of 52-week high74%4

1-year return+18%7

3-year return+176%9

5-year return+255%9

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +176% over three years and +255% over five, ahead of 80% of the market.

Strong recent results. The stock is outperforming so far this year (+23%).

WATCH

It's up 18% over the past year, but 26% below its 52-week high. That is a touch ahead of the market.

Returns sit at the market level over the past month (-4%) and over three months (-5%).

WEAKNESSES

None flagged.

BOTTOM LINE

Steady Compounder

Dependable multi-year returns with a calmer near-term tape. A reliable long-term trend rather than a short-term breakout.

04Value

Are you paying a fair price for it?

Stop guessing on Haisco Pharmaceutical Group Co., Ltd.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community